Braveheart Bio website screenshot

Braveheart Bio

Braveheart Bio is a late clinical-stage biopharmaceutical company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiac conditions. Its lead candidate, BHB-1893, is a selective cardiac myosin inhibitor (licensed as HRS-1893 from Hengrui Pharma) designed to reduce excessive heart-muscle contraction and improve cardiac performance in patients with obstructive and non-obstructive HCM. The San Francisco-based company launched in November 2025 with a $185M Series A led by a16z alongside Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences, and filed for a Nasdaq IPO in July 2026. Braveheart Bio is a corporate/scientific organization and does not currently publish a public developer program, API, or SDKs.

Braveheart Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Cardiovascular, and Hypertrophic Cardiomyopathy.

Braveheart Bio’s developer surface includes engineering blog and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
11.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyBiopharmaceuticalCardiovascularHypertrophic CardiomyopathyDrug DevelopmentLife SciencesClinical Stage

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 11.2/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.4 / 20
Commercial Clarity 2.1 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/braveheart: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Braveheart Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 3

The organization behind the API

Website
Website
 About
About
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: braveheart
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/braveheart.png
name: Braveheart Bio
description: Braveheart Bio is a late clinical-stage biopharmaceutical company developing novel therapeutics for hypertrophic
  cardiomyopathy (HCM) and related cardiac conditions. Its lead candidate, BHB-1893, is a selective cardiac myosin inhibitor
  (licensed as HRS-1893 from Hengrui Pharma) designed to reduce excessive heart-muscle contraction and improve cardiac performance
  in patients with obstructive and non-obstructive HCM. The San Francisco-based company launched in November 2025 with a $185M
  Series A led by a16z alongside Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences, and filed for a Nasdaq IPO
  in July 2026. Braveheart Bio is a corporate/scientific organization and does not currently publish a public developer program,
  API, or SDKs.
url: https://raw.githubusercontent.com/api-evangelist/braveheart/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- Forbion
- OrbiMed
- Enavate Sciences
- Frazier Life Sciences
x-tier: stub
x-tier-reason: portfolio-lead
x-industry: biotechnology
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Cardiovascular
- Hypertrophic Cardiomyopathy
- Drug Development
- Life Sciences
- Clinical Stage
apis: []
common:
- type: Website
  url: https://www.braveheart.bio
- type: About
  url: https://www.braveheart.bio/about
- type: Blog
  url: https://www.braveheart.bio/news
- type: PrivacyPolicy
  url: https://www.braveheart.bio/privacy-policy
- type: DomainSecurity
  url: security/braveheart-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence